β-Blockers and sudden cardiac death

Annals of Internal Medicine

Volumn 123, Issue 5, 1995, Pages 358-367

  Kendall, Martin J ^a   Lynch, Kevin P ^a   Hjalmarson, Åke ^b   Kjekshus, John ^c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

METOPROLOL; PROPRANOLOL; SOTALOL; TIMOLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SUDDEN DEATH; TREATMENT PLANNING;

EID: 0029101157     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-123-5-199509010-00007     Document Type: Review

References (113)

1. Arteriosclerosis 1981: report of the Working Group on Arteriosclerosis of the National Heart, Lung, and Blood Institute. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health; 1981; DHEW, NIH Publ No. 82-2035:114-22.
2. Surawicz B. Prevention of sudden cardiac death: three promising approaches. Rhythmology. 1987;11:3-10.
3. Kannel WB, Doyle JT, McNamara PM, Quickenton P, Gordon T. Precursors of sudden coronary death: Factors related to the incidence of sudden death. Circulation. 1975;51:606-13.
4. Rajman I, Kendall MJ. Sudden cardiac death and the potential role of beta-adrenoceptor-blocking drugs. Postgrad Med J. 1993;69:903-11.
5. Myerburg RJ, Castellanos A. Cardiac arrest and sudden death. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. 4th ed. Philadelphia: WB Saunders; 1992:756.
6. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med. 1984;311:1144-7.
7. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-38.
8. Furukawa T, Bassett AL, Furukawa N, Kimura S, Myerburg RJ. The ionic mechanism of reperfusion-induced early afterdepolarizations in feline left ventricular hypertrophy. J Clin Invest. 1993;91:1521-31.
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
10. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982;248:1465-77.
11. Yusuf S, Teo KK. Approaches to prevention of sudden death: need for fundamental reevaluation. J Cardiovasc Electrophysiol. 1991;2: S233-9.
12. Kannel WB, Cupples LA, D'Agostino RB, Stokes J 3d, Hypertension, antihypertensive treatment, and sudden coronary death. The Framingham Study. Hypertension. 1988;11(3 Pt 2):II45-50.
13. Levy D, Wilson PW, Anderson KM, Castelli WP. Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study. Am Heart J. 1990;119:712-7.
14. Cutler JA, MacMahon SW, Furburg CD.Controlled clinical trials of drug treatment for hypertension. A review. Hypertension. 1989;13(5 Suppl):I36-44.
15. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255-64.
16. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992;304:405-12.
17. Olsson G, Tuomilehto J, Berglund G, Elmfeldt D, Warnold I, Barber H, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens. 1991;4:151-8.
18. Kaplan NM. Critical comments on recent literature: SCRAAPHY about MAPHY from HAPPHY. Am J Hypertens. 1988;1(4 Pt 1):428-30.
19. Moser M, Sheps S. Confusing messages from the newest of the beta-blocker/diuretic hypertension trials. The Metoprolol Atherosclerosis Prevention in Hypertensives trial. Arch Intern Med. 1989;149: 2174-5.
20. Wikstrand J, Kendall M. The role of beta receptor blockade in preventing sudden death. Eur Heart J. 1992;13(Suppl D):111-20.
21. Fletcher A, Beevers DG, Bulpitt C, Butler A, Coles EC, Hunt D, et al. Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens. 1988;2:219-27.
22. Green KG. British MRC trial of treatment for mild hypertension - a more favorable interpretation [Letter]. Am J Hypertens. 1991;4:723-4.
23. Dahlof B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-5.
24. Pasternak RC, Braunwald E, Sobel BE. Acute myocardial infarction. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. 4th ed. Philadelphia: WB Saunders; 1992:1200.
25. Elwood PC. Aspirin in the prevention of myocardial infarction. Current status. Drugs. 1984;28:1-5.
26. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-71.
27. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-7.
28. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707-14.
29. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Mélek I, Nyberg G, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;2:823-7.
30. Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D, Herlitz J, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. 1992;13:28-32.
31. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet. 1986;2:57-66.
32. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J. 1985;6:199-226.
33. Held P, Yusuf S. Early intravenous beta-blockade in acute myocardial infarction. Cardiology. 1989;76:132-43.
34. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet. 1982;i:1142-7.
35. Yusuf S, Furberg CD. Effects of calcium channel blockers on survival after acute myocardial infarction [Editorial]. Cardiovasc Drugs Ther. 1987;1:343-4.
36. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med. 1988;319:385-92.
37. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-77.
38. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821-8.
39. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58, 050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995; 345:669-85.
40. Pentecost BL, Austen WG. Beta-adrenergic blockade in experimental myocardial infarction. Am Heart J. 1966;72:790-6.
41. Fearon RE. Propranolol in the prevention of ventricular fibrillation due to experimental coronary artery occlusion. Am J Cardiol. 1967; 20:222-8.
42. Khan MI, Hamilton JT, Manning GW. Protective effect of beta adrenoceptor blockade in experimental coronary artery occlusion in conscious dogs. Am J Cardiol. 1972;30:832-7.
43. Ablad B, Bjurö T, Björkman JA, Edström T, Olsson G. Role of central nervous beta-adrenoceptors in the prevention of ventricular fibrillation through augmentation of cardiac vagal tone. J Am Coll Cardiol. 1991;17(Suppl):165.
44. Parker GW, Michael LH, Hartley CJ, Skinner JE, Entman ML. Central β -adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs. Circ Res. 1990;66:259-70.
45. Dellsperger KC, Martins JB, Clothier JL, Marcus ML. Incidence of sudden cardiac death associated with coronary artery occlusion in dogs with hypertension and left ventricular hypertrophy is reduced by chronic β -adrenergic blockade. Circulation. 1990;82:941-50.
46. Hjalmarson Å. Empiric therapy with beta-blockers. PACE Pacing Clin Electrophysiol. 1994;17(3 Pt 2):460-6.
47. Rydén L, Ariniego R, Arnman K, Herlitz J, Hjalmarson Ä, Holmberg S, et al. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med. 1983;308:614-8.
48. Huikuri HV, Cox M, Interian A Jr, Kessler KM, Glicksman F, Castellanos A, et al Efficacy of intravenous propanolol for suppression of inducibility of ventricular tachyarrhythmias with different electrophysiologic characteristics in coronary artery disease. Am J Cardiol. 1989;64:1305-9.
49. Rutherford JD, Braunwald E. Chronic ischemic heart disease. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. 4th ed. Philadelphia: WB Saunders; 1992:1307.
50. Anderson JL, Rodier HE, Green LS. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol. 1983;51:1196-202.
51. Morganroth J, Bigger JT Jr, Anderson JL. Treatment of ventricular arrhythmias by United States cardiologists: a survey before the Cardiac Arrhythmia Suppression Trial results were available. Am J Cardiol. 1990;65:40-8.
52. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989;321:406-12.
53. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992;327:227-33.
54. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. A meta-analysis. Circulation. 1991;84:1977-83.
55. Anderson JL. Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial. J Clin Pharmacol. 1990;30:981-9.
56. Kennedy HL, Goldstein S, Barker AH, Brooks MM, Huther M, Beanlands DS, et al. Beta-blocker therapy and congestive heart failure in the Cardiac Arrhythmia Suppression Trial (CAST). J Am Coll Cardiol. 1993;21:378A.
57. Hallstrom AP, Cobb LA, Yu BH, Weaver WD, Fahrenbruch CE. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol. 1991;68: 1025-31.
58. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med. 1993; 329:452-8.
59. Waldo AL, Camm AJ, de Ruyter H, Friedman PL, MacNeil DJ, Pitt B, et al. Preliminary mortality results from the Survival with Oral D-Sotalol (SWORD) Trial [Abstract]. J Am Coll Cardiol. 1995; :15A.
60. Hohnloser SH, Woosley RL. Sotalol. N Engl J Med. 1994;331:31-8.
61. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 1990;16:1711-8.
62. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344:493-8.
63. Gurwitz JH, Goldberg RJ, Chen Z, Gore JM, Alpert JS. β -blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly. Am J Med. 1992;93:605-10.
64. Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs. Drugs. 1986;32:335-57.
65. Huffman BB, Lefkowitz RJ. Adrenergic receptor antagonists. In: Goodman LS, Gilman A, Gilman AG et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Pr; 1990:233.
66. Östlund-Lindqvist AM, Lindqvist P, Bräutigam J, Olsson G, Bondjers G, Nordborg C. The effect of metoprolol on diet-induced atherosclerosis in rabbits. Arteriosclerosis. 1988;8:40.
67. Lindqvist P, Olsson G, Nordborg C, Bondjers G, Bräutigam J, Östlund-Lindqvist A. Atherosclerosis in rabbits identified as high and low responders to an atherogenic diet and the effect of treatment with a beta 1-blocker. Atherosclerosis. 1988;72:163-72.
68. Camejo G, Hurt E, Thrubikar M, Bondjers G. Modification of low density lipoprotein association with the arterial intima. A possible environment for the antiatherogenic action of beta-blockers. Circulation. 1991;84(6 Suppl):V117-22.
69. Olsson G, Bondjers G, Dählof C, Hjalmarsson A, Sandberg A, Ablad B, et al. Cardioselective β-adrenoceptor blockers. In: Messerli FH, ed. Cardiovascular Drug Therapy. Philadelphia: WB Saunders; 1990:497-8.
70. Teger-Nilsson AC, Dahlöf C, Haglund E, Hedman C, Olsson G, Ablad B. Influence of metoprolol CR/ZOK on plasminogen activator inhibitor (PAI-1) in man: a pilot study. J Clin Pharmacol. 1990;30(2 Suppl):S132-7.
71. Åblad B, Björkman JA, Edvardsson N, Hansson G. A beta-adrenergic mechanism in the arterial wall possibly involved in genesis of cardiovascular disease. Fed Proc. 1987;46:974.
72. Winther K, Hedman C, Beta-adrenoceptor blockade, platelets, and rheologic factors. Cephalalgia. 1986;6(Suppl 5):33-9.
73. Thubrikar MJ, Roskelley SK, Eppink RT. Study of stress concentration in the walls of the bovine coronary arterial branch. J Biomech. 1990;23:15-26.
74. DeBakey ME, Lawrie GM, Glaeser DH. Patterns of atherosclerosis and their surgical significance. Ann Surg. 1985;201:115-31.
75. Baker JW, Thubrikar MJ, Parekh JS, Forbes MS, Nolan SP. Change in endothelial morphology at arterial branch sites caused by a reduction on intramural stress. Atherosclerosis. 1991;89:209-21.
76. Thubrikar MJ, Keller AC, Holloway PW, Nolan SP. Distribution of low density lipoprotein in the branch and non-branch regions of the aorta. Atherosclerosis. 1992;97:1-9.
77. Thubrikar MJ, Baker JW, Nolan SP. Inhibition of atherosclerosis associated with reduction of arterial intramural stress in rabbits. Arteriosclerosis. 1988;8:410-20.
78. Thubrikar MJ, Christie AM, Cao-Denh HC, Holloway PW, Nolan SP. Metoprolol reduces low density lipoprotein uptake in aortic regions prone to atherosclerosis. FASEB J. 1990;4:A1151.
79. Lager I, Blohme G, Smith U. Effect of cardioselective and non-selective β-blockade on the hypoglycaemic response in insulin-dependent diabetics. Lancet. 1979;1:458-62.
80. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-8.
81. Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ. 1989;229:1127-31.
82. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-44.
83. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol. 1988;128:389-401.
84. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986;57:43F-9F.
85. Farrell TG, Bashir Y, Cripps T, Malik M, Poloniecki J, Bennett ED, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal averaged electrocardiogram. J Am Coll Cardiol. 1991;18:687-97.
86. Bigger JT, Fleiss JL, Rolnitzky LM, Steinman RC. Frequency domain measures of heart period variability to assess risk late after myocardial infarction. J Am Coll Cardiol. 1993;21:729-36.
87. Ewing DJ, Campbell IW, Clarke BF. Mortality in diabetic autonomic neuropathy. Lancet. 1976;1:601-3.
88. Kahn JK, Sisson JC, Vinik AI. Prediction of sudden cardiac death in diabetic autonomic neuropathy. J Nucl Med. 1988;29:1605-6.
89. Herlitz J, Elmfeldt D, Holmberg S, Málek I, Nyberg G, Pennert K, et al. Göteborg Metoprolol Trial: mortality and causes of death. Am J Cardiol. 1984;53:9D-14D.
90. Gullestad L, Kjekshus J. Myocardial disease in diabetes mellitus. Tidsskr Nor Laegeforen. 1992;112:1016-9.
91. Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J. 1990;11:43-50.
92. Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care. 1983;6:285-90.
93. Malmberg K, Herlitz J, Hjalmarson Å, Rydén L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J. 1989;10:423-8.
94. Black JW, Stephenson JS. Pharmacology of a new adrenergic beta-receptor-blocking compound (Nethalide). Lancet. 1962;2:311-4.
95. Herlitz J, Hjalmarson A, Holmberg S, Swedberg K, Vedin A, Waag stein F, et al. Development of congestive heart failure after treatment with metoprolol in acute myocardial infarction. Br Heart J. 1984;51:539-44.
96. Hansteen V, Minichen E, Lorentsen E, Andersen A, Strm O, Siland K, et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. BMJ. 1982;284:155-60.
97. Furberg CD, Hawkins CM, Lichstein E. Effect of propranolol in postinfarction patients with mechanical or electrical implications. Circulation. 1984;69:761-5.
98. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73:503-10.
99. Lichstein E, Hager WD, Gregory JJ, Fleiss JL, Rolnitzky LM, Bigger JT Jr. Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. The Multicenter Diltiazem Post-Infarction Research Group. J Am Coll Cardiol. 1990;16:1327-32.
100. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022-36.
101. Eichhorn EJ, Hjalmarson Å. Beta-blocker treatment for chronic heart failure. The frog prince [Editorial]. Circulation. 1994;90:1765-73.
102. Hjalmarson Å, Waagstein F. The role of beta-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Drugs. 1994; 47(Suppl 4):31-9.
103. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term β-blockade in dilated cardiomyopathy. Effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989;80:551-63.
104. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441-6.
105. Fowler MB, Bristow MR. Rationale for beta-adrenergic blocking drugs in cardiomyopathy. Am J Cardiol. 1985;55:120D-124D.
106. Gottlieb SS. β-Blockers for heart failure: where are we now? Curr Opin Cardiol. 1994;9:295-300.
107. Bashir Y, McKenna WJ, Camm AJ. β blockers and the failing heart: is it time for a U-turn? Br Heart J. 1993;70:8-12.
108. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314:1657-64.
109. Hjemdahl P, Wiklund IK. Quality of life on antihypertensive drug therapy: scientific end-point or marketing exercise? [Editorial] J Hypertens. 1992;10:1437-46.
110. Schoenberger JA, Croog SH, Sudilovsky A, Levine S, Baume RM. Self-reported side effects of antihypertensive drugs. A clinical trial. Am J Hypertens. 1990;3:123-32.
111. Steiner SS, Friedhoff AJ, Wilson BL, Wecker JR, Santo JP. Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol. J Hum Hypertens. 1990;4:217-25.
112. Thiessen BQ, Wallace SM, Blackburn JL, Wilson TW, Bergman U. Increased prescribing of antidepressants subsequent to β-blocker therapy. Arch Intern Med. 1990;150:2286-90.
113. Dahlöf C, Dimenäs E, Kendall M, Wiklund I. Quality of life in cardiovascular diseases. Emphasis on β-blocker treatment. Circulation. 1991;84(6 Suppl):VI108-18.